Gvoke HypoPen is the first ready-to-use glucagon in a premixed autoinjector, with no visible needle
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that Gvoke HypoPen (glucagon injection) is now available by prescription in the U.S. for the treatment of severe hypoglycemia in adults and children with diabetes ages 2 years and above.
Gvoke HypoPen is the first ready-to-use glucagon in a premixed autoinjector, with no visible needle.
Gvoke HypoPen offers simple administration with the certainty of delivery. Studies have shown it is:
Easy to use: premixed and ready-to-go
A reliable method of delivery: 99% of people were able to use it correctly
Proven to work: 99% of adults and 100% of kids had their blood sugars raised to safe levels.
Gvoke HypoPen is available in two doses: 0.5 mg/0.1 mL for children (who weigh less than 100 pounds) and 1 mg/0.2 mL for adolescents and adults (who weigh 100 pounds or greater).
“We are excited to announce that Gvoke HypoPen is now available. The simplicity and reliability of Gvoke HypoPen has the potential to change people’s ability to confidently respond to a severe hypoglycemic event in a timely manner,” said Paul R. Edick, Chairman and Chief Executive Officer of Xeris Pharmaceuticals. “In addition, as we prepared for launch, we had a heightened focus on ensuring Gvoke HypoPen is covered by insurance. Currently, approximately 78% of commercially insured and Medicare lives have unrestricted access to Gvoke HypoPen.”
“Gvoke HypoPen allows the diabetes community to change how we approach treating severe low blood sugar events,” said Bruce Bode, MD, FACE, Atlanta Diabetes Associates. “Anyone can use Gvoke HypoPen in two simple steps. That opens the door for some patients to even give it to themselves, in certain situations. My hope is that what was once considered a crisis moment, can now become a manageable situation with Gvoke HypoPen.”
Xeris is committed to ensuring that patients have access to this important new advancement. For a limited time, eligible commercially insured patients may pay as little as $0 for a two-pack of Gvoke HypoPen by using the Gvoke® copay savings card*. Xeris also offers a Patient Assistance Program to help those who qualify to get Gvoke.
Source: Company Press Release